Castle Biosciences (CSTL) Revenue & Revenue Breakdown
Castle Biosciences Revenue Highlights
Latest Revenue (Y)
$344.23M
Latest Revenue (Q)
$103.55M
Main Segment (Y)
Dermatologic
Castle Biosciences Revenue by Period
Castle Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $344.23M | 3.66% |
| 2024-12-31 | $332.07M | 51.09% |
| 2023-12-31 | $219.79M | 60.38% |
| 2022-12-31 | $137.04M | 45.65% |
| 2021-12-31 | $94.08M | 50.18% |
| 2020-12-31 | $62.65M | 20.79% |
| 2019-12-31 | $51.87M | 127.62% |
| 2018-12-31 | $22.79M | 65.67% |
| 2017-12-31 | $13.75M | - |
Castle Biosciences generated $344.23M in revenue during NA 2025, up 3.66% compared to the previous quarter, and up 549.46% compared to the same period a year ago.
Castle Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | $103.55M | 23.74% |
| 2026-03-31 | $83.68M | -3.83% |
| 2025-12-31 | $87.01M | 4.78% |
| 2025-09-30 | $83.04M | -3.65% |
| 2025-06-30 | $86.19M | -2.05% |
| 2025-03-31 | $87.99M | 1.94% |
| 2024-12-31 | $86.31M | 0.62% |
| 2024-09-30 | $85.78M | -1.40% |
| 2024-06-30 | $87.00M | 19.22% |
| 2024-03-31 | $72.97M | 10.37% |
| 2023-12-31 | $66.12M | 7.52% |
| 2023-09-30 | $61.49M | 22.65% |
| 2023-06-30 | $50.14M | 19.27% |
| 2023-03-31 | $42.04M | 9.65% |
| 2022-12-31 | $38.34M | 3.59% |
| 2022-09-30 | $37.01M | 6.24% |
| 2022-06-30 | $34.84M | 29.74% |
| 2022-03-31 | $26.85M | 7.24% |
| 2021-12-31 | $25.04M | 6.66% |
| 2021-09-30 | $23.48M | 3.15% |
| 2021-06-30 | $22.76M | -0.24% |
| 2021-03-31 | $22.81M | 31.87% |
| 2020-12-31 | $17.30M | 13.68% |
| 2020-09-30 | $15.22M | 19.68% |
| 2020-06-30 | $12.71M | -27.00% |
| 2020-03-31 | $17.42M | -1.23% |
| 2019-12-31 | $17.63M | 19.35% |
| 2019-09-30 | $14.77M | 37.59% |
| 2019-06-30 | $10.74M | 23.19% |
| 2019-03-31 | $8.72M | -23.78% |
| 2018-12-31 | $11.44M | 208.10% |
| 2018-09-30 | $3.71M | -6.73% |
| 2018-06-30 | $3.98M | 8.77% |
| 2018-03-31 | $3.66M | - |
Castle Biosciences generated $103.55M in revenue during Q2 2026, up 23.74% compared to the previous quarter, and up 117.68% compared to the same period a year ago.
Castle Biosciences Revenue Breakdown
Castle Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Dermatologic | $216.37M | $257.00M | $183.38M | $124.81M | $85.75M |
| Service, Other | - | - | - | $12.23M | $8.33M |
Latest
Castle Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 25: Dermatologic (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dermatologic | $48.70M | $41.10M | $48.59M | $48.52M | $56.30M | $62.96M | $63.77M | $65.06M | $68.83M | $59.33M | $53.28M | $51.15M | $43.03M | $35.91M | $34.65M | $33.92M | $31.90M | $24.34M |
| Service, Other | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.69M | $3.09M | $2.94M | $2.51M |
Latest
Castle Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Dermatologic (100.00%).
Castle Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMN | AMN Healthcare Services | $2.73B | $673.24M |
| EVH | Evolent Health | $1.88B | $652.52M |
| EMBC | Embecta | $1.08B | $271.70M |
| MYGN | Myriad Genetics | $824.50M | $190.70M |
| CDNA | CareDx | $379.81M | $131.95M |
| CSTL | Castle Biosciences | $344.23M | $103.55M |
| FLGT | Fulgent Genetics | $322.67M | $85.39M |
| GERN | Geron | $183.88M | $57.48M |
| VIR | Vir Bio | $68.56M | $238.95M |
| DRIO | DarioHealth | $22.36M | $5.18M |
| PSNL | Personalis | - | - |